Compare AbbVie Inc (ABBV) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? AbbVie Inc trades at $254.21 (market cap $449.91B), while State Street Real Estate Select Sector SPDR ETF trades at $44.22. The key difference: AbbVie Inc pays a 2.72% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and AbbVie Inc is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | XLRE | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $45.36 |
52-Week Low | $184.85 | $40.01 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
XLRE trades at $44.29, down 0.9% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a low 0.08% expense ratio and focuses exclusively on U.S. real estate investment trusts. Recent news highlights XLRE's cost advantage over global real estate ETFs and discusses the REIT sector's resilience amid interest rate volatility.
The outlook for XLRE hinges on U.S. real estate fundamentals and interest rate trends. Opportunities include potential sector recovery and durable dividends, but risks remain from rising Treasury yields and economic uncertainty. Wall Street sentiment is mixed, with technicals suggesting near-term consolidation around key support at $44.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
